KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AbbVie
Astellas Pharma Inc
Amgen
AbbVie
Actuate Therapeutics Inc.
Eli Lilly and Company
AstraZeneca